Healthy, Type 2 Diabetes
Conditions
Brief summary
Platelet activation has been associated with bad events like heart attack and stroke. There are a variety of platelet activators that regulate how active a platelet is. We are interested in Protease-activated receptors (PAR)-1. We are currently studying PAR-1 activation in persons with severe peripheral artery disease. We seek, through this project, to understand PAR-1 activation in persons without peripheral artery disease. As many patients with peripheral artery disease have diabetes, we will also evaluate PAR-1 activation in persons with type 2 diabetes. In addition we will assess the impact of the glucagon-like peptide (GLP)-1 signaling pathway on platelet activation. Levels of platelet activation will be determined using platelet aggregation experiments and assessment of platelet-monocyte aggregates in peripheral blood.
Interventions
None listed
Sponsors
Vanderbilt University Medical Center
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy men and women ≥60 years of age OR * Type 2 diabetic men and women ≥60 years of age
Exclusion criteria
* Active cancer * Prior myocardial infarction, prior stroke, diagnosed peripheral artery disease * Severe liver (cirrhosis, cancer, or end-stage liver disease), kidney disease (eGFR \<30 cc/min). * Pregnancy or lactation * Active vasculitis * Anticipated lifespan \< 2 years * Current use of a DOAC
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Platelet Activation | One day | Number of dilysyl-MDA cross-links formed in human platelets |
| Protease Activated Receptor-1 Activation | One day | Number of cleaved PAR-1 receptors in proportion to number of uncleared PAR-1 receptors |
Countries
United States
Outcome results
None listed